Make your money go further for just 25p per day

AIM IHT

Novacyt reassures…to a degree

Covid test

The clinical diagnostics specialist has finally announced its full year results. While these offered a degree of clarity on the dispute with the DHSC, investors should be more focused on the future potential. Here are some 'back of the envelope' thoughts on the current valuation.  


AIM’s top performer in 2020, clinical diagnostics specialist Novacyt (LON:NCYT), issued the much anticipated (and long-awaited) results for the year ending 31 December 2020.

The shares have been very weak following news of the company’s dispute with the UK’s Department of Health and Social Care (‘DHSC’) so followers were looking for some clarity. We covered the dispute in our earlier update here.

The key numbers for the year ending December 2020 were truly fabulous…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Novacyt SA

A Covid tester is back in favour

26/11/2021 · Company Insights

AIM was already having a challenging month and news of a new strain of Covid-19 coming…


Big price moves - more to go for?

27/09/2021 · Company Insights

Shares in a company we have covered since IPO soared on strong results and a very…


More Company Insights

A Covid tester is back in favour

Bonkers Bargains: ridiculously cheap with ESG appeal (Updated)

26/11/2021 · Bonhill Group

Sign-up to our free email updates

SIGN UP